A 3D VIEW Targeting Inflammatory Mechanisms in Pursuit of Clinical Remission and Mucosal Healing: A Personalized Approach to IBD Therapy

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

Saturday, December 15, 2018

6:30 AM Eastern    05:30 AM Central    04:30 AM Mountain    03:30 AM Pacific

FACULTY

Gerald W. Dryden, MD, PhD, MSPH, MSc
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Louisville Physicians Outpatient Center
Louisville, KY

Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
 

• A Satellite Symposium held in conjuction with the 2018 Advances in Inflammatory Bowel Diseases Conference: Multidisciplinary Approaches to IBD Patient-Centered Care

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

• Describe signaling pathways that affect IBD pathophysiology and the role of Janus kinase (JAK) pathways in cytokine effects
• Discuss interpretations of laboratory and physical findings in addition to the mucosal status to optimize appropriate IBD therapy
• Identify clinical applications of available and emerging agents to reach treat-to-target therapeutic goals

Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Med Learning Group. Imedex is accredited by the ACCME to provide continuing medical education for physicians.

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME), Imedex and Med Learning Group. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENT

Imedex, LLC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

This continuing nursing education activity awards 1.0 contact hour. This activity will also award pharmacotherapeutic contact hours; however, the final assignment of these contact hours will be announced once all content has been approved. Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hours.

Accreditation Statement

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

DISCLOSURE POLICY STATEMENT

As an accredited provider of continuing medical education, Imedex, LLC and NACCME, LLC require anyone in a position to affect the activity’s subject matter to disclose any financial relationships they have as related to the contents of their presentations. The existence of commercial or financial interests of presenters related to the subject matter of their presentations should not be construed as implying bias or decreasing the value of their presentations. However, disclosure should help participants form their own judgments. All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.

DISCLOSURE OF UNLABELED USE

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) of the United States or European Medicines Agency (EMA). Participants are encouraged to consult the EMA-approved or FDA-approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed in this document are the opinions of the presenters and do not necessarily reflect the opinions of Imedex, LLC and/or NACCME, LLC.

DISCLAIMER

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither HMP, NACCME, Imedex nor any of its subsidiaries or affiliates, is affiliated with or formally endorsed by a medical society.

Contact this CME provider at Imedex for privacy and confidentiality policy statement.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

This program is not affiliated with Digestive Disease Week^®.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.